Skip to main content

Quince Therapeutics, Inc.

corporate_fare Company Profile

Quince Therapeutics, Inc.

QNCX·NASDAQ·Life Sciences·CIK 0001662774

Quince Therapeutics, Inc. is a biotechnology company that previously focused its development activities on treating rare diseases using a patient's own biology. The company's proprietary AIDE technology platform is an innovative drug/device combination designed to automatically encapsulate a drug into a patient's own red blood cells. This technology aimed to leverage the characteristics of red blood cells for drug delivery, potentially offering benefits such as improved safety and tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolonged circulating half-life. The AIDE platform was designed to apply to a wide range of small or large molecule drugs and biologics. The company's lead asset, eDSP, utilized the AIDE technology to encapsulate DSP into a patient's red blood cells. In January 2026, Quince Therapeutics completed its pivotal Phase 3 NEAT clinical trial, which evaluated eDSP for the treatment of A-T, a rare pediatric neurodegenerative disease. The primary endpoint of the NEAT study, which measured the change from baseline to the last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo, did not achieve statistical significance. Consequently, eDSP does not appear to be an effective treatment for A-T, and the company will not continue its development for this or other therapeutic indications. Quince Therapeutics currently has no other product candidates and lacks sufficient resources to pursue further research and development activities. The company is focused on preserving cash while evaluating strategic alternatives. On February 9, 2026, LifeSci Capital was engaged as the exclusive financial advisor to assist with restructuring activities and the evaluation of strategic alternatives.

Quince Therapeutics, Inc. (NASDAQ:QNCX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for QNCX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for QNCX spans 8-K, DEF 14A, 10-Q, PRE 14A.

Recent high-impact activity:

  • Quince Therapeutics Names Brigette Roberts CEO Amid Restructuring
  • Quince Therapeutics Rebrands as IRulya Therapeutics with New Leadership and $116M Cash Runway Through 2028
  • Quince Stockholders Approve Series C Conversion, Authorized Share Increase, and New Equity Plans
  • Quince Sells AIDE/eDSP Assets for $450K, Finalizes President's $1M Severance
  • Nasdaq Delisting Notice Hits Quince Therapeutics on Negative Equity

Dilution Risk

Low risk

Filing-implied dilution signals for QNCX, detected from its recent SEC filings.

1 shelf registrationreverse split

S-3 Amendment Filed · Resale Registration Details

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with Q →
$31.73
52-week range · as of 2026-10-09 $15.1 – $909.98
Market cap
$32.27M
Volume
138.7K (5.2× avg)
3-mo avg 26.7K
Last traded · 2026-10-12

show_chartPrice Chart

Loading chart...

feed QNCX - Latest Insights

QNCX
Oct 09, 2026, 8:10 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.00
Real-time Price: $31.73 info
Change: +$0.730 (+2%) info
Market Cap: $32.271M info
QNCX
Oct 09, 2026, 7:59 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $29.36
Real-time Price: $31.73 info
Change: +$2.37 (+8%) info
Market Cap: $32.271M info
QNCX
Oct 06, 2026, 4:57 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.81
Real-time Price: $31.73 info
Change: +$4.92 (+18%) info
Market Cap: $32.271M info
QNCX
Sep 14, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.59
Real-time Price: $31.73 info
Change: +$3.14 (+11%) info
Market Cap: $32.271M info
QNCX
Sep 04, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $30.55
Real-time Price: $31.73 info
Change: +$1.18 (+4%) info
Market Cap: $32.271M info
QNCX
Aug 27, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.50
Real-time Price: $31.73 info
Change: -$0.770 (-2%) info
Market Cap: $32.271M info
QNCX
Aug 25, 2026, 8:30 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $31.78
Real-time Price: $31.73 info
Change: -$0.050 (-0.16%) info
Market Cap: $32.271M info
QNCX
Aug 17, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $34.04
Real-time Price: $31.73 info
Change: -$2.31 (-7%) info
Market Cap: $32.271M info
QNCX
Aug 14, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $34.04
Real-time Price: $31.73 info
Change: -$2.31 (-7%) info
Market Cap: $32.271M info
QNCX
Aug 14, 2026, 8:21 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.50
Real-time Price: $31.73 info
Change: -$0.770 (-2%) info
Market Cap: $32.271M info
QNCX
Aug 14, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $32.50
Real-time Price: $31.73 info
Change: -$0.770 (-2%) info
Market Cap: $32.271M info
QNCX
Jul 31, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.30
Real-time Price: $31.73 info
Change: +$8.43 (+36%) info
Market Cap: $32.271M info
QNCX
Jul 31, 2026, 4:48 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $23.30
Real-time Price: $31.73 info
Change: +$8.43 (+36%) info
Market Cap: $32.271M info
QNCX
Jul 31, 2026, 4:45 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $31.73 info
Change: +$8.43 (+36%) info
Market Cap: $32.271M info
QNCX
Jul 30, 2026, 6:02 AM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $18.99
Real-time Price: $31.73 info
Change: +$12.74 (+67%) info
Market Cap: $32.271M info
QNCX
Jun 26, 2026, 4:31 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.927
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Jun 26, 2026, 9:18 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9533
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Jun 11, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
May 21, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
May 21, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets